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INTRODUCTION
With widespread utilization of noninvasive cross-sec-
tional abdominal imaging, small solid renal masses
are being found with increasing frequency 1. These
small tumours are often discovered incidentally by ab-
dominal ultrasound or computer tomography (CT).
These incidentally discovered renal tumours are gen-
erally slower growing, are detected at an earlier stage,
and are localized to the kidney 2,3. The triad of pain,
hematuria, and palpable mass is now more the excep-
tion than the rule. Many patients now treated for renal
cell carcinoma (RCC) are asymptomatic at presentation.
The radical nephrectomy has been the “gold stan-
dard” for the treatment of clinically localized RCCs,
but a shift has occurred toward treating small, inci-
dentally found renal neoplasms in a nephron-sparing
manner. Nephron-sparing techniques have been shown
to offer oncologic and functional outcomes that are
equivalent to those with radical nephrectomy for pa-
tients with renal tumours 4 cm or smaller in size 4–6.
Since the mid 1990s, the movement toward mini-
mally invasive alternatives has meant the replacement
of open surgery (radical or partial nephrectomy) with
laparoscopic techniques and now with in situ abla-
tive technologies 7,8. Ablative techniques offer advan-
tages over extirpative techniques by reducing
perioperative morbidity, shortening the hospital stay,
promoting faster recovery, and importantly, poten-
tially treating patients who are poor surgical candi-
dates while preserving renal parenchyma 9,10.
Several ablative technologies have been investi-
gated, among them, cryoablation (CA), radiofrequency
ablation (RFA), microwave 11, high-intensity focused
ultrasound 12,13, laser interstitial thermotherapy 14,
microwave thermotherapy, and radiosurgery. The
current outcomes with RFA and CA are promising, but
long-term studies are ongoing to validate their onco-
logic efficacy and durability.
This overview briefly outlines advances in en-
ergy-ablative techniques for RCC and provides a syn-
opsis of recent clinical studies of RFA and CA.
RADIOFREQUENCY ABLATION
Radiofrequency ablation is a heat-mediated method
of tissue destruction. The technology was initially
developed for treating primary and metastatic liver
lesions 15. Zlotta et al. first described the use of RFA
as the primary treatment for small renal tumours in
1997 16. In recent years, RFA has become the most
commonly used percutaneous ablative technique for
RCCs. Its use has been described in patients with small
renal tumours who have poor renal reserve, multiple
bilateral RCC in Von Hippel–Lindau, or hereditary
RCCs, or in those who are poor surgical candidates 17.
Contraindications to RFA include an uncorrected
coagulopathy, acute illness or infection, recent myo-
cardial event, and poor life expectancy. Tumour fac-
tors predicting RFA failure include large tumours
(larger than 4 cm) and tumours in the hilum or the
collecting system.
Radiofrequency ablation works by transmitting
a high-frequency electrical current through an elec-
trode placed directly into the renal tumour. Alternat-
ing current delivered through the probe causes ions
in the surrounding tissues to vibrate, creating fric-
tional heat that results in heat-induced tissue dam-
age. The mechanism of tissue destruction has been
extensively reviewed 18.
At a molecular level, the heat generated by the
high-frequency electrical current causes tissue de-
struction in three phases. Immediately post-ablation,
molecular friction produces some combination of
destruction of cellular structure, protein denaturation,
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membrane lipid melting, and cellular vaporiza-
tion 18,19. Days after the ablation, coagulative necro-
sis with surrounding areas of cellular edema and
inflammation is evident and leads to tumour destruc-
tion 19,20. The final evolution of the ablated tissue is
re-absorption of the necrotic foci; the resulting fibrotic
scar is non-enhancing on contrast imaging 21.
The success of tumour ablation with RFA depends
on factors including probe temperature, generator
power, temperature distribution, and targeting of the
tumour 22–26.
For the cellular changes to occur as described ear-
lier, temperatures above 50°C must be achieved. Ear-
lier underpowered RFA generators have been replaced
by new generators with upwards of 200 W that can
consistently achieve temperatures above 100°C. How-
ever, temperatures higher than 105°C cause immedi-
ate vaporization and boiling of tissue, which creates
gas bubbles, tissue carbonization, and eschar forma-
tion at the electrode. These effects increase imped-
ance and reduce the extent of tissue ablation 20.
Many studies have aimed to achieve electrode
temperatures between 50°C and 100°C. Innovations
to reduce the impedance created at high temperatures
include infusion of hypertonic saline into the target
tissue during ablation. Electrodes are also designed in
variously-sized configurations from single and mul-
tiple tines to expandable hooks. The radiofrequency
may be applied using a temperature-based or imped-
ance-based system 24,27. Finally, RFA may be applied
percutaneously or laparoscopically 7,21,28,29. Ultra-
sonography,  CT, and magnetic resonance imaging (MRI)
have all been used to target lesions. Now, with the
advent of fluoroscopic CT and open interventional MRI,
real-time ablation monitoring can be achieved.
Table I summarizes recently published studies on
RFA. To date, Matsumoto et al. have reported the larg-
est series: 109 tumours treated with percutaneous
RFA 34. The mean tumour size was 2.4 cm, and initial
ablation was successful in 107 of the 109 tumours. A
recurrence rate of 2.8% was reported during a mean
follow-up of 19 months.
Similarly, Gervais et al. reported 100 tumours
treated with percutaneous RFA 31. The tumour sizes
ranged from 1.1 cm to 8.9 cm, with 9 tumours rang-
ing in size from 4.0 cm to 8.9 cm and requiring mul-
tiple ablation sessions. All tumours smaller than 4.0 cm
were ablated completely after a single course. These
authors reported 79 lesions with no-contrast-enhance-
ment CT at a mean follow-up period of 28 months.
The most recent study by Varkarakis et al. reports
the ablation of 56 tumours with a mean tumour size
of 2.2 cm. No residual tumour was detected on CT for
47 lesions at a mean follow-up time of 27 months 30.
The RFA procedure is not without complications.
In a multi-institutional review of complications of
cryoablation and radiofrequency ablation of small
renal tumours, Johnson et al. reported 11 complica-
tions in 133 cases (8.2%) 40. The most commonly re-
ported complication was pain and paresthesia at the
site of electrode insertion for percutaneous RFA 40. Stud-
ies have also reported perinephric hematoma, obstruc-
tion at the ureteropelvic junction, ureter damage, ileus,
and urine leak 41. Ureteropelvic junction scarring re-
quiring nephrectomy has also been reported 42.
CRYOABLATION
Cryoablation (or cryotherapy) involves freezing the
target tissue with a cryoprobe in situ. The tumour is
rapidly frozen, creating a cryolesion, which then un-
dergoes necrosis over time and eventually heals by
secondary intention. At a molecular level, the dam-
age induced by the cryo-energy is two-fold 43. Ini-
tially, the freezing causes direct cell damage through
rapid extracellular and intracellular freezing and ice
formation. As a result, extracellular osmotic concen-
trations change, cell membranes become dysfunc-
tional, and cell integrity is disrupted. Indirect
cryotherapy-induced damage is caused by the impair-
ment of tissue microvasculature by vasoconstriction,
endothelial damage, microvascular thrombosis, and
tissue ischemia 44,45. In addition, an immunologic re-
sponse is also induced, resulting in further reaction
to the neoplastic tissue 46. The success of cryoablation
depends not only on the freezing and thawing cycles,
but also on the lowest temperature that is reached
and the duration for which that temperature is held.
Argon or nitrogen are the cryogens most com-
monly used for cooling to a temperature of –40°C,
and their effect usually extends 1 cm beyond the le-
sion margin 47. Cell death in normal and neoplastic
tissue occurs reliably at that temperature.
Cryoablation differs from RFA in that the extremes
of temperature alone are not enough to completely
destroy cells; the effects of delayed microvascula-
ture failure are also required. The contraindications
for cryotherapy are similar to those for RFA.
Cryoablation can be performed by open 48,
laparoscopic, and percutaneous techniques 10,49,50.
Unlike RFA, cryoablation requires real-time monitor-
ing of the ice ball to ensure that the tumour is com-
pletely frozen and to minimize injury to the
surrounding healthy tissue. To date, most cryoablation
has been performed using laparoscopic techniques
under ultrasound monitoring. An open or inter-
ventional  MRI has been used to permit real-time moni-
toring of the ice ball in a percutaneous approach 10.
Recently, a group from Johns Hopkins published re-
sults of percutaneous cryoablation using real-time
fluoroscopic CT 51.
Gill et al. published the first series of patients
undergoing cryoablation in 1998 54. Table II summa-
rizes recent studies on cryoablation for small renal
tumours.
Gill et al. 54,59 have reported the largest series of
patients undergoing cryoablation to date. With 56 of
115 patients completing 3 years of follow-up at theKWAN and MATSUMOTO
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time of publication, tumour size was reduced by 75%,
and 2 patients showed malignancy in 6-month post-
ablation CT-guided biopsy.
Cestari 57 et al. reported a series of 37 patients
undergoing laparoscopic cryoablation. The mean fol-
low-up time was 20.5 months, and 25 patients who
underwent the postoperative CT-guided biopsies had
negative results.
Most recently, Lawatsch et al. 52 reported a se-
ries of 59 patients undergoing laparoscopic cryo-
ablation. Mean follow-up time was 26.8 months. Two
recurrences were identified after cryoablation.
In a multi-institutional review of complications
of cryoablation and RFA of small renal tumours,
Johnson et al. reported complications in 139 cases
(13.6%) 40. As with RFA, pain and paresthesia at the
site of probe insertion were the most commonly re-
ported complications 40.
CONCLUSION
With the number of incidentally detected small renal
tumours increasing and minimally invasive techniques
for treating those tumours becoming more common,
investigators have turned toward energy-ablative tech-
nologies. In particular, small asymptomatic renal
masses in older patients or in those who are poor can-
didates for surgery require treatment in a minimally
invasive fashion with minimal morbidity.
Radiofrequency ablation and cryoablation both
appear to be safe and effective methods of treating
small renal tumours. Both can be deployed in a mini-
mally invasive fashion, with percutaneous RFA being
the least cumbersome approach. Percutaneous
cryoablation requires real-time monitoring of the ice
ball, and because of the need for open MRI or fluoro-
CT few centers have performed this technique to date.
TABLE II Recent studies on cryoablation for renal tumours
Reference Patients Mean tumour Approach Follow-up Nephrectomy
(n) size or range (cm) (months) needed (n)
Lawatsch et al., 2006 52 59 2.5 Lap 26.8 1
Bachmann et al., 2005 53 7 2.6 Lap 13.6 0
Gill et al., 2005 54 56 2.3 Lap 36 0
Silverman et al., 2005 55 23 2.6 Perc 14 0
Bassigiani et al., 2004 56 4 2.8 Perc 7 0
Cestari et al., 2004 57 37 2.6 Lap 20.5 0
Moon et al., 2004 58 16 2.6 Lap 9.6 0
Lee et al., 2003 44 20 2.6 Lap 14.2 0
Shingleton and Sewell, 2002 10 20 3.0 Perc 9.1 0
Lap = laparoscopy; Perc = percutaneous.
TABLE I Recent studies on radiofrequency ablation for renal tumours
Reference Patients Tumours Mean tumour Tumour type Approach Success Follow-up
(n)( n) size or range Exophytic Parenchymal, on CT (months)
(cm) central, or mixed (%)
Varkarakis et al., 2005 30 46 56 2.2 39 17 Perc 84 (47/56) 27
Gervais et al., 2005 31 85 100 1.1–8.9 67 33 Perc 99 (79/80) 28
Hwang et al., 2004 32 17 24 2.2 10 14 Lap=15 96 (23/24) 13
Perc=9
Lewin et al., 2004 33 10 10 2.3 10 0 Perc 100 (10/10) 25
Matsumoto et al., 2004 34 91 109 2.4 N/A N/A Lap=46 98 (107/109) 19
Perc=63
Ukimura et al., 2004 35 9 9 3.8 5 3 Perc 78 (7/9) 17
Zagoria et al., 2004 25 22 24 3.5 9 15 Perc 100 (<3 cm) 7
69 (>3 cm)
Farrell et al., 2003 36 20 35 1.7 22 13 Perc 100 (35/35) 9
Mayo–Smith et al., 2003 37 32 32 2.6 29 3 Perc 100 (32/32) 9
Roy–Choudhury et al., 2003 38 8 11 3.0 9 2 Perc 88 (7/8) 17
Su et al., 2003 39 29 35 2.2 28 7 Perc 100 (35/35) 9
Ogan et al., 2002 29 12 13 2.4 10 3 Perc 92 (12/13) 5
Pavlovich et al., 2002 7 21 24 2.4 13 11 Perc 79 (19/24) 2
CT = computed tomography; Perc = percutaneous; Lap = laparoscopic.ABLATION OF RENAL TUMOURS
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The early results appear promising; however, long-
term follow-up data are needed to prove the efficacy
and durability of both ablative technologies.
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